Blair William & Co. IL Acquires 709,677 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Key Points

• Blair William & Co. IL increased its holdings in Vigil Neuroscience by 219.1% during the 1st quarter, owning over 1 million shares valued at approximately $1.84 million.
• Several institutional investors, including Cubist Systematic Strategies LLC and Barclays PLC, also boosted their stakes in Vigil Neuroscience during the fourth quarter, indicating growing confidence in the stock.
• Despite recent downgrades from multiple analysts, Vigil Neuroscience's consensus rating remains a "Hold", with a target price of $10.80.

Blair William & Co. IL lifted its position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 219.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,033,577 shares of the company's stock after purchasing an additional 709,677 shares during the period. Blair William & Co. IL owned about 2.10% of Vigil Neuroscience worth $1,840,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Cubist Systematic Strategies LLC boosted its holdings in Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares during the last quarter. Jane Street Group LLC acquired a new position in Vigil Neuroscience in the fourth quarter valued at approximately $83,000. Barclays PLC lifted its stake in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the period. Northern Trust Corp lifted its stake in Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP lifted its stake in Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock valued at $117,000 after buying an additional 49,000 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL remained flat at $8.05 on Monday. The stock has a fifty day moving average price of $7.99 and a two-hundred day moving average price of $4.53. Vigil Neuroscience, Inc. has a 1 year low of $1.31 and a 1 year high of $8.10. The company has a market capitalization of $383.90 million, a PE ratio of -3.93 and a beta of 3.33.

Analyst Upgrades and Downgrades

VIGL has been the topic of several recent analyst reports. Citizens Jmp lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim set a $8.00 price target on Vigil Neuroscience and gave the company a "neutral" rating in a research note on Thursday, May 22nd. Mizuho lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Wedbush lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and lowered their target price for the stock from $13.00 to $8.00 in a research report on Thursday, May 22nd. Finally, Stifel Nicolaus lowered Vigil Neuroscience from a "buy" rating to a "hold" rating and lowered their target price for the stock from $11.00 to $8.00 in a research report on Wednesday, May 28th. Ten equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $10.80.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.